Italfarmaco S.p.A. and JCR Pharmaceuticals Co., Ltd. (TSE 4552; "JCR"), today announced an exclusive licensing agreement for the development and commercialisation of givinostat in Japan. Under the ...
Discover why Edgewise Therapeutics, Inc. is rated Buy amid strong trial data, unique HCM treatment, and major 2026 catalysts. Click for this EWTX update.
As of Wednesday, December 24, Edgewise Therapeutics, Inc.’s EWTX share price has surged by 20.17%, which has investors questioning if this is right time to sell.
DelveInsight’s "Duchenne Muscular Dystrophy Pipeline Insight 2025” report provides comprehensive insights about 75+ companies and 75+ pipeline drugs in the Duchenne Muscular Dystrophy pipeline ...
Discusses HOPE-3 Phase III Trial Results and Regulatory Path for Duchenne Muscular Dystrophy Therapy December 17, ...
The US HHS has added Duchenne muscular dystrophy and metachromatic leukodystrophy to newborn screening, citing benefits of early detection and access to FDA-approved treatments.
IN a heartfelt effort to enhance the quality of life for her son, a mother from Durban has turned to crowdfunding to raise funds for a specialised bed to keep her son, who has end-stage Duchenne ...
The Enquirer and United Way of Greater Cincinnati have joined forces for the 39th year to help families in need with the Wish List program. After wishes are granted, remaining funds assist people with ...
U.S. Health Secretary Robert F. Kennedy Jr. on Tuesday added two rare genetic disorders, Duchenne Muscular Dystrophy and ...
HHS has announced the addition of Duchenne muscular dystrophy and metachromatic leukodystrophy to the Recommended Uniform ...
Health secretary Robert F. Kennedy Jr. on Tuesday added two deadly rare diseases, Duchenne muscular dystrophy and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback